Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fimbrial antigen type 3 is a bacterial surface protein complex classified as a fimbria or pilus, primarily found on the surface of many Gram-negative bacteria. These structures are composed of polymeric protein subunits—mainly pilin—and function as key adhesins that enable bacteria to bind specifically to glycoprotein or glycolipid receptors on host cell surfaces. This adhesion is critical for initial colonization, biofilm formation, and resistance to physical removal from tissues. The adhesive tip at the end of each fimbria determines receptor specificity and can vary between strains, contributing both to tissue tropism and immune evasion. Proteins associated with fimbriae act as antigens that stimulate adaptive immunity by being recognized by antibodies and lymphocyte receptors. While not an enzyme or classical receptor in human pharmacology terms, "Fimbrial antigen type 3" is considered a valid therapeutic target due to its essential role in infection establishment by pathogenic bacteria such as Escherichia coli[1][2][3].
Inhibition would block bacterial adhesion to host cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fimbrial antigen type 3.